An observational study in Folliculitis Decalvans and Staphylococcus Aureus, sponsored by Assistance Publique - Hôpitaux de Paris. Completed at 1 site in France. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2016-06-24.
Sponsored by Assistance Publique - Hôpitaux de Paris · Observational
The folliculitis decalvans (FD) is an orphan disease , common in consultation specialized on scalp. This disease is currently not curable, responsible for significant for patients. The pathophysiology is poorly understood, Staphylococcus aureus (SA) appears to play a role, never previously studied, and the study will attempt to clarify it.
Controversies in the literature on the pathophysiological hypotheses can be summed up as follows :
FD is it an infectious folliculitis where SA (almost always found on the lesions plays a direct role possibly aided by a lack of local immune protection , or is it a pustular inflammatory unknown cause where the SA has no direct role but is a cofactor or a simple germ superinfection.
Our study has plans to bring new evidence to help decide between these two opposite but not mutually exclusive concepts .
278 studies on the registry are indexed under Staphylococcal Infections; 29 are open to participants now.
This study's enrollment of 40 is below the median of 198 across 82 observational studies indexed under Staphylococcal Infections.
Browse Staphylococcal Infections studies →Assistance Publique - Hôpitaux de Paris is the lead sponsor of 3,576 studies on the registry; 1,028 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Adult patients with Folliculitis Decalvans
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patient with a folliculitis Decalvans
Other: no intervention : case control study
Control without folliculitis decalvans
Other: no intervention : case control study
presence of Staphylococcus Aureus in cutaneous biopsies (at least one colony)
The primary endpoint is the presence of Staphylococcus Aureus in cutaneous biopsies before any therapy and notably antibiotics.
Time frame: 1 day
presence of Staphylococcus Aureus in cutaneous biopsies (at least one colony) after treatment
Time frame: 10 weeks
presence of Staphylococcus Aureus in nasal swab (at least one colony)
Time frame: 1 day
This study is completed, as verified in Mar 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Assistance Publique - Hôpitaux de Paris →